Literature DB >> 11328265

Evaluation of five commercial serological tests for the detection of Helicobacter pylori infection in Chinese.

M L Szeto1, C K Lee, Y K Yee, K F Li, W K Lee, C C Lee, T L Que, B C Wong.   

Abstract

BACKGROUND: Commercial serological tests for the detection of Helicobacter pylori infection must be locally validated. We evaluated the accuracy of five commercial tests in the Chinese population.
METHODS: Serum samples were collected from patients referred for upper endoscopy. Antral biopsies were taken for histological examination and culture of H. pylori. The gold standard for diagnosing H. pylori infection was positive histological staining and/or positive H. pylori culture. The serum samples were tested for H. pylori antibodies using the following tests: (i) Cobas Core Anti-H. pylori EIA; (ii) GAP IgG; (iii) GAP IgM; (iv) H. pylori microwell EIA (Quidel); and (v) Premier H. pylori. The sensitivity, specificity and accuracy of each test was calculated according to the manufacturers' instructions or according to a new cut-off value.
RESULTS: A total of 158 patients were recruited amongst whom 114 (72%) were H. pylori-positive. Indeterminate results varied from 7% to 19%. The accuracy of the tests varied from 57% to 85%. By using new cut-off values, the accuracy was much improved, ranging from 73.4% to 86.7%.
CONCLUSIONS: By defining new cut-off values for the Chinese population, we were able to improve the performance of some of the serology tests. This illustrates the importance of local validation.

Entities:  

Mesh:

Year:  2001        PMID: 11328265     DOI: 10.1046/j.1365-2036.2001.00961.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  1 in total

1.  The influence of cytokine gene polymorphisms on the risk of developing gastric cancer in patients with Helicobacter pylori infection.

Authors:  David Stubljar; Samo Jeverica; Tomislav Jukic; Miha Skvarc; Tadeja Pintar; Bojan Tepes; Rajko Kavalar; Borut Stabuc; Borut Peterlin; Alojz Ihan
Journal:  Radiol Oncol       Date:  2015-08-21       Impact factor: 2.991

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.